Futura Posts Early Maiden Profit, Revenue and Earnings to Surge

September 10, 2024 06:44 PM AEST | By Team Kalkine Media

Google News:

Futura Posts Early Maiden Profit, Revenue and Earnings to Surge — Image source: Shutterstock

Recent News

Carney launches ‘One Canadian Economy’ Act to unify trade, approvals

Trump signs orders to enhance drone defenses, support supersonic trave...

US job growth in May tops forecasts, but Macquarie warns cracks are em...

U.S. Treasury, Commerce secretaries and Trade Representative to meet C...

Futura Medical PLC (LSE:FUM) has announced a significant milestone in its financial performance for the first half of 2024, marking its first profit of £1 million on revenues of £7 million. The company closed the period with a strong balance sheet, holding £3.9 million in cash.

The positive financial results come as Futura prepares for the upcoming U.S. launch of its erectile dysfunction gel, Eroxon, in partnership with Haleon, a spinoff from GSK. This gel is noted for its rapid onset of action, providing users with an erection within ten minutes. Eroxon is already available for pre-order in the U.S. with deliveries scheduled for October and subsequent availability in stores. This development triggers the next milestone payment from Haleon, mirroring the scale of previous payments.

CEO James Barder highlighted the achievement, stating, “It is a significant milestone to be able to announce our first profit, a year after the initial pilot launch of Eroxon, and well ahead of market expectations.” Barder emphasized that this profit marks the beginning of Eroxon's potential, positioning it as a key player in the underserved sexual health market.

In addition to its European successes in countries such as France, Italy, and Spain, Futura Medical is set to further expand its market presence in 2024. To support increasing demand, the company has secured partnerships with two new contract manufacturers to enhance its supply chain and production capacity.

Furthermore, Futura Medical has extended its licensing agreement with Cooper until 2029, ensuring ongoing market access for its products. The company’s strategic steps and financial achievements underscore its commitment to growth and innovation in the healthcare sector.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.